These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 34476668)

  • 21. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?
    Koufakis T; Mustafa OG; Ajjan RA; Garcia-Moll X; Zebekakis P; Dimitriadis G; Kotsa K
    J Clin Pharm Ther; 2020 Oct; 45(5):883-891. PubMed ID: 31905245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
    Neuen BL; Arnott C; Perkovic V; Figtree G; de Zeeuw D; Fulcher G; Jun M; Jardine MJ; Zoungas S; Pollock C; Mahaffey KW; Neal B; Heerspink HJL
    Diabetes Obes Metab; 2021 Feb; 23(2):382-390. PubMed ID: 33043620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
    Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
    Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
    Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
    van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
    Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
    Katsiki N; Mikhailidis DP; Theodorakis MJ
    Curr Pharm Des; 2017; 23(10):1522-1532. PubMed ID: 28088910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular benefit of SGLT2 inhibitors.
    Mohebi R; Januzzi JL
    Crit Rev Clin Lab Sci; 2022 May; 59(3):142-155. PubMed ID: 34784839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
    van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
    JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
    Kadowaki T; Yamamoto F; Taneda Y; Naito Y; Clark D; Lund SS; Okamura T; Kaku K
    Expert Opin Drug Saf; 2021 Jun; 20(6):707-720. PubMed ID: 33706621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease.
    Koufakis T; Liberopoulos EN; Kotsa K
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):357-361. PubMed ID: 35292920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.
    Chi C; Snaith J; Gunton JE
    Heart Lung Circ; 2017 Nov; 26(11):1133-1141. PubMed ID: 28473214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.
    Ali MU; Mancini GBJ; Fitzpatrick-Lewis D; Lewis R; Jovkovic M; Zieroth S; O'Meara E; Connelly KA; Sherifali D
    Can J Cardiol; 2022 Aug; 38(8):1201-1210. PubMed ID: 35961756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.
    Akiyama H; Nishimura A; Morita N; Yajima T
    Front Endocrinol (Lausanne); 2023; 14():1111984. PubMed ID: 36793276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
    Nevola R; Alfano M; Pafundi PC; Brin C; Gragnano F; Calabrò P; Adinolfi LE; Rinaldi L; Sasso FC; Caturano A
    Rev Cardiovasc Med; 2022 Mar; 23(3):106. PubMed ID: 35345273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.